Immune Rejuvenation
Key Takeaways
- Immunosenescence includes reduced naive T-cell output, altered immune memory, and weaker responses to some novel threats.
- Inflammaging describes chronic, low-grade inflammatory signalling that is associated with multiple age-related diseases.
- Thymic involution is a major research target, but evidence for clinically meaningful reversal in general ageing remains limited.
- Engineered immune-cell approaches, including senolytic CAR-T models, are mostly preclinical in ageing contexts.
The Dual Burden: Immunosenescence and Inflammaging
The ageing immune system shows both reduced adaptive flexibility and increased inflammatory tone. Immunosenescence includes reduced naive T-cell production, clonal expansion of memory cells, and weaker responses to some infections and vaccines. Inflammaging refers to chronic, low-grade inflammatory signalling from innate immune cells, senescent cells, damaged tissues, and other sources. These patterns are studied as contributors to age-related disease, but reversing them safely is difficult because immune activation and immune suppression both carry risks.
Reversing Thymic Involution
The thymus is the anatomical site of T-cell maturation. Unlike most organs, the thymus begins atrophying during puberty—its functional lymphoid tissue is progressively replaced by adipocytes (fat cells). By age 70, the thymus outputs less than 5% of the naive T-cells it did in early life.
Several avenues are being studied in relation to thymic involution:
- Recombinant cytokines and growth factors: Small human studies, including TRIIM, have examined combinations such as recombinant human growth hormone, DHEA, and metformin. Findings are preliminary and require larger controlled replication.
- Senescent-cell targeting: Clearing senescent cells from immune niches is a plausible mechanism under study, but thymus-specific evidence remains early.
- Keratinocyte growth factor (KGF): KGF has clinical use in specific oncology-support settings and is studied for effects on thymic epithelial cells, but this is not evidence of a general anti-ageing therapy.
Engineered Senolytic Interventions: CAR-T Cells
CAR-T cells are engineered immune cells designed to recognize specific surface markers. In ageing research, one experimental idea is to target markers enriched on senescent cells, such as uPAR. This approach could in principle improve selectivity compared with broadly acting small molecules, but marker specificity, tissue distribution, persistence, and safety are unresolved.
In 2020, Amor et al. reported that uPAR-targeted CAR-T cells cleared senescent cells and improved outcomes in mouse models of lung cancer and liver fibrosis. This is an important proof-of-concept, but it does not establish broad senescent-cell clearance as safe or effective for human ageing.
Challenges in Application
Immune therapies can carry serious risks. Cytokine release syndrome is a known complication of some cell therapies, and immune modulation can also increase infection, autoimmunity, or malignancy risk depending on context. Because immune ageing is system-wide and heterogeneous, studies need to separate short-term biomarker changes from durable clinical benefit.
References
- Fahy, G. M. et al. "Reversal of epigenetic aging and immunosenescent trends in humans." Aging Cell (2019). https://doi.org/10.1111/acel.13028
- Amor, C. et al. "Senolytic CAR T cells reverse senescence-associated pathologies." Nature (2020). https://doi.org/10.1038/s41586-020-2403-9
This content is provided for academic reference only and does not constitute advice. Experimental immunotherapy models discussed here are largely limited to preclinical trials.